bcl-2 is known to play a crucial role in modulating carcinoma progression as well as in inhibiting apoptosis. However, its expression and clinical significance for cholangiocellular carcinoma (CCC) remains unclear. In the present study, we immunohistochemically investigated bcl-2 expression in 41 CCC. Thirteen cases (31.7%) were classified as bcl-2 positive, because more than 10% of the carcinoma cells expressed bcl-2. The expression of bcl-2 was inversely related to lymph node metastasis, vascular invasion, perineural invasion, the Ki-67 labeling index, aberrant p53 expression and the incidence of apoptotic cells. Furthermore, well or moderately differentiated carcinoma more frequently expressed bcl-2. These results suggest that downregulation of bcl-2 expression is strongly linked to highly biologically aggressive phenotypes of CCC.

Keywords:
bcl-2, Cholangiocellular carcinoma, Immunohistochemistry
1.
Cleary ML, Sklar J: Nucleotide sequence of a t(14:18) chromosomal break point in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985;82:7439–7443.
2.
Tsujimoto Y, Jaffe E, Cossman J, Gorham J, Nowell PC, Croce CM: Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature 1985;315:340–343.
3.
Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, Korsmeyer SJ: Cloning the chromosomal breakpoint of t(14:18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985;41:899–906.
4.
Vaux DL, Cory S, Adams JM: bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440–442.
5.
Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1991;348:334–336.
6.
Borzillo GV, Endo K, Tsujimoto Y: bcl-2 confers growth and survival advantage to interleukin 7-dependent early pre-B cells which become factor independent by a multiple process in culture. Oncogene 1992;7:869–876.
7.
Hockenberry DM, Zutter M, Hickey W, Nahm M, Korsmeyer S: bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961–6965.
8.
Chow N-H, Liu H-S, Yang H-B, Chan S-H, Su I-J: Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. Virchows Arch 1997;430:461–466.
9.
Joensuu H, Pylkkanen L, Toikkanen S: bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994;145:1191–1198.
10.
Sinicrope FA, Hart J, Michelassi F, Lee JJ: Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res 1995;1:1103–1110.
11.
Toramen U, Eerola AK, Rainio P, Vahakangas K, Soini Y, Sormunen R: Enhanced apoptosis predicts shortened survival in non-small lung carcinoma. Cancer Res 1995;55:5595–5602.
12.
Colombel M, Synmans F, Gil S: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390–400.
13.
Sarbia M, Bittinger F, Porschen R, Verreet P, Dutkowski P, Willers R: bcl-2 expression and prognosis in squamous-cell carcinomas of the esophagus. Int J Cancer 1996;69:324–328.
14.
Fausto N: Hepatocytes differentiation and liver progenitor cells. Curr Opin Cell Biol 1990;2:1036–1042.
15.
MacDonald RA: ‘Lifespan’ of liver cells. Arch Intern Med 1961;107:335–343.
16.
Charlotte F, L’Hermine A, Martin N, Geleyn Y, Nollet M, Gaulard P, Zafrani ES: Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. Am J Pathol 1994;144:460–465.
17.
Terada T, Nakanuma Y: Expression of apoptosis, proliferating cell nuclear antigen and apoptosis-related antigens (bcl-2, c-myc, Fas, Lewis(y) and p53) in human cholangiocarcinomas and hepatocellular carcinomas. Pathol Int 1996;46:764–770.
18.
Zhano M, Zhang N-X, Economou M, Blaha I, Laissue JA, Zimmermann A: Immunohistochemical detection of bcl-2 protein in liver lesions: bcl-2 protein is expressed in hepatocellular carcinomas but not in liver cell dysplasia. Histopathology 1994;25:237–245.
19.
Kerr JFR, Wyllie AH, Currie AR: Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1971;26:239–257.
20.
Higaki K, Yano H, Kojiro M: Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am J Pathol 1996;149:429–437.
21.
Ito Y, Matsuura N, Sakon M, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Monden M: Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer, in press.
22.
Liver Cancer Study Group of Japan: The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, ed 3. Tokyo, Kanehara, 1992.
23.
Pichlmayr R, Lamesch P, Weimann A, Tusch G, Ringe B: Surgical treatment of cholangiocellular carcinoma. World J Surg 1995;19:83–88.
24.
Nozaki Y, Yamamoto M, Ikai I, Yamamoto Y, Ozaki N, Fujii H, Nagahori K, Matsumoto Y, Yamaoka Y: Reconsideration of the lymph node metastasis pattern (N factor) from intrahepatic cholangiocarcinoma using the International Union against Cancer TNM staging system for primary liver carcinoma. Cancer 1998;83:1923–1926.
25.
Sasaki K, Murakami T, Kawasaki M: The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol 1987;133:579–584.
26.
Kondo E, Yoshino T, Nomura S, Nakamura S, Takahashi K, Teramoto N, Hayashi K, Akagi T: bcl-2 regulation in normal resting lymphocytes and lymphoblasts. Jpn J Cancer Res 1994;85:260–265.
27.
Knowlton K, Mancini M, Creason S, Morales C, Hockenbery D, Anderson BO: Bcl-2 slows in vitro breast cancer growth despite its antiapoptotic effect. J Surg Res 1998;76:22–26.
28.
Pollina L, Pacini F, Fontanini G, Vignati S, Bevilacqua G, Basolo F: bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br J Cancer 1996;73:139–143.
29.
Kakalamanis L, Savage A, Mortensen N, Tsiotos P, Doussis-Anagnostopoulou I, Biddolph S, Whitehouse R, Harris A, Gatter KC: Early expression of bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia. J Pathol 1996;179:10–14.
30.
Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U: The bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499–504.
31.
Watson AJM, Merritt AJ, Jones LS, Askew JN, Anderson E, Becciolini A, Balzi M, Potten CS, Hickman JA: Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 1996;73:889–895.
32.
Baas IO, Mulder J-WR, Johan G, Offerhaus A, Vogelstein B, Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5–12.
33.
Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB: Bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597–608.
34.
Kozopas KM, Yant G, Buchan HL, Zhou P, Vcraig RW: MCL 1, a gene expression in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 1993;90:3516–3520.
35.
Lin EY, Orlofsky A, Berger MS, Prystowsky MB: Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol 1993;151:1979–1988.
36.
Oltvai ZN, Milliman CL, Korsmeyuer SJ: Bcl-2 heterodimerizes in vivo with a conserved homologue, bax, that accelerates programmed cell death. Cell 1993;74:609–619.
37.
Chittenden T, Harrington EA, O’Conner R, Remington C, Lutz RJ, Evans GI, Guild BC: Induction of apoptosis by the bcl-2 homologue bak. Nature 1995;374:733–736.
38.
Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ: Bac, a heterodimeric partner for Bcl-xL, and Bcl-2, displaces bax and promotes cell death. Cell 1995;80:285–291.
39.
Rochaix P, Krajewski S, Reed JC, Bonnet F, Voigt J-J, Brousset P: In vivo patterns of bcl-2 family protein expression in breast carcinoma in relation to apoptosis. J Pathol 1999;187:410–415.
40.
Krajewska M, Fenoglilo-Preiser CM, Krajewski S, Song K, Macdonald JS, Stemmerman G, Reed JC: Immunohistochemical analysis of bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 1996;149:1449–1457.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.